MARY WATTS

H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025

HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)

HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)

H.R. 8890: Enhancing CLIA Act of 2026

H.R.3152/S.1546: Patent Eligibility Restoration Act

H.R.5269/S.2761 - RESULTS Act Calendar Year 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Proposed Rule (CMS-1850-P) CY 2027 Payment Policies under the Medicare Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies (CMS-1848-P)

H.R.6624/S.3452 - Biological Intellectual Property Protection Act of 2025

HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)

S.3741 - Biosecurity Modernization and Innovation Act of 2026 Regulation for Federal Financial Assistance

S.3741 - Biosecurity Modernization and Innovation Act of 2026

HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)

HR 8792/S.4513: Multigenerational Caregivers Data Act HR 6766/S3492: Essential Caregivers Act HR 2036/S 925 Credit for Caring Act Docket No. FDA-2026-P-3666-0001: Requests that the FDA codify, regularize, and transparently administer a principle the Agency already recognizes in practice: that the adequacy of an investigation in rare diseases cannot be determined by default assumptions alone. It does not ask FDA to invent a new principle or apply distinct evidentiary thresholds or concessions to rare disease research programs. Drug Repurposing for Unmet Medical Needs; Request for Information (FDA-2026-N-4492) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comment (FDA-2026-N-3947)